Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?

Introduction and context :

Glomerulonephritis and auto-immune diseases are often associated. Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which have a severe impact on prognosis. This complication is a real challenge for clinicians because of insidious-onset and no predictable relapses. Biomarker use is therefore essential, but conventional biomarkers such as proteinuria, glomerular filtration rate, urine sediments, anti-dsDNA antibodies and complement levels, have poor sensivity and low specificity to predict LN occurrence, and new more reliable biomarkers (such as genetic, epigenetic or protein biomarkers) are difficult to use for daily medical practice , .

Anti-glomerular membrane basement disease (anti-GBM disease) is a rare (0.5 to 1/millions of inhabitants , ) and severe illness , , characterised by rapidly progressive glomerulonephritis, pulmonary haemorrhage and the presence of anti-GBM antibodies, which are highly sensible (100%) and specific (92-100%) of this condition .

In our department of internal medicine, one case of Goodpasture glomerulonephritis associated to an active SLE has been reported , and after searching data in literature, we note the following studies:

• some similar cases were reported such as a case of pulmonary hemorrhage and positive anti-GBM in SLE , or a case of anti-GBM disease and LN presenting as pulmonary-renal syndrome .
• In 2006, a Chinese cohort study highlighted an elevated prevalence of anti-GBM antibodies, in serum samples from patients with SLE (14 positives/157patients (8.9%) with ELISA method). Moreover, every patient with positive anti-GMB antibodies had LN and a severer SLE (with more anemias, pulmonary hemorrhage). They also suffered from more important kidney disease. In fact, in histological criteria's, 10/14 had necrotizing crescentic glomerulonephritis lesions and 5/14 had a real diagnosis of Goodpasture disease.
• We also note that some authors have already studied pathogenesis of this association (whether immunological explanations , genetics links , ).

• Main Hypothesis: Based on these findings, we suspect that detection of positive circulating anti-GBM antibodies may be more frequently positive in SLE followed patients (than in general population) and that it could be an interesting screening biomarker for LN.

• Objectives First objective: based on 2 SLE patient groups (one having lupus nephritis and another without it) we would like to compare the ratio of positive anti-GBM antibodies in each group, expecting a higher rate in SLE patients with LN.

Second objective: to study positive anti-GBM patients in their clinical aspects, serological features and renal characteristics, in this SLE population.

• Materials and methods We suggest a retrospective analytic transversal controlled study, based on serum samples from the Lupus Biobank of Upper Rhine (LBBR project), and on serum samples from healthy voluntary blood donors (control group).

Regarding the use of LBBR Lupus Biobank, our project has already been accepted by scientific committee.

After group randomization, Cryo-conserved SLE serum samples will be transferred by specialized transporter service, from Strasbourg biobank, to the immunology laboratory department in Reims University Hospital center, to perform anti-GBM tests.

Concerning healthy serum sample recruitment, Regional blood center of Reims will systematically suggest to voluntary blood donors to participate. If they agree, they will receive an extended information about the study, and after written consent, a tube sample will be collected.

• Population The statistic calculation led to the need of 200 SLE sera (100 patients in each group). Thus, we will use : 100 serum samples coming from lupus biobank LBBR patients without lupus nephritis, and 100 serum samples of patients with systemic lupus erythematosus and lupus nephritis.

We will also use 100 serum samples of voluntary blood donors.

• Experimental project Anti-GBM antibodies detection in serums will be performed by an automatized chemiluminescent method, using a commercial test kit. In case of positivity, same serum will be tested second time to confirm the result, and then controlled by another method using indirect immunofluorescence (IIF) in frozen sections of primate kidney, covering the reaction areas of a BIOCHIP slide (reference method).

According to our immunology laboratory department, we need 600μl of serum per patient to be able to perform all the tests. According to the manufacturer's instruction, the optimum cut-off value for positivity in chemiluminescence method will be set at 20CU/mL.

• Data analysis Primary endpoint: proportion of positive anti-MBG antibodies, will be estimated in each group (with and without lupus nephritis) by a Chi-2 test or an exact test of Fisher (depending on test validity conditions).

Secondary endpoint: clinical, serological and renal features of anti-GBM positives patients, will be compared to negatives, using tests adapted to the distribution of each variable.

• Expected results and future prospects

• We expect a higher frequency of positive circulating anti-GBM antibodies in patients with LN compared to the SLE control group and to healthy control group.
• Whether this research was positive, another larger study could show the interest of anti-GBM antibodies as a predictive biomarker of LN, and as a prognostic biomarker of SLE.

Inclusion criteria

• serum samples coming from LBBR lupus biobank (diagnosis of lupus according ACR criteria or diagnosis of lupus nephritis according to ISN/RPS2003) or serum sample coming from healthy bload donor volunters
• having signed the informed consent

Exclusion criteria

• diagnosis of lupus nephritis and having a beginning kidney disease (every class I and II of WHO classification and class I or II of ISN/RPS classification)
• lack of data regarding kidney histology on clinical LBBR file
• minor healthy blood donor
• healthy blood donor volunters with auto immune disease, or kidney disease, or chronic renal failure or taking immunosuppressive or immunomodulatory therapy or with history of cutaneous lupus or SLE